Neuroendocrine effects of quetiapine in healthy volunteers

International Journal of Neuropsychopharmacology

Volumn 8, Issue 1, 2005, Pages 49-57

  De Borja Gonçalves Guerra, Alexandro ^a   Castel, Saulo ^a   Benedito Silva, Ana Amélia ^a   Calil, Helena Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ACTH; Cortisol; Growth hormone; Prolactin; Quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CORTICOTROPIN; DOPAMINE 2 RECEPTOR; GROWTH HORMONE; HISTAMINE H1 RECEPTOR; HYDROCORTISONE; PLACEBO; PROLACTIN; QUETIAPINE; SEROTONIN 2 RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR;

ADENOHYPOPHYSIS; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RECEPTOR BINDING; DYSTONIA; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HYDROCORTISONE RELEASE; MALE; MEASUREMENT; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; TACHYCARDIA; XEROSTOMIA;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; ANTIPSYCHOTIC AGENTS; AROUSAL; CROSS-OVER STUDIES; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; PITUITARY GLAND; PROLACTIN; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE H1; RECEPTORS, SEROTONIN, 5-HT2;

EID: 15244363181     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004705     Document Type: Article

References (64)

1. 2 receptor in the 5-HT receptor-mediated stimulation of prolactin release. European Journal of Pharmacology 251, 157-161.
2. Ali JA, Desai KD, Ali LJ (2003). Delusions of pregnancy associated with increased prolactin concentrations produced by antipsychotic treatment. International Journal of Neuropsychopharmacology 6, 111-115.
3. Allolio B, Winkelmann W, Deuss U, Heesen D, Hipp FX, Miles R (1980). Effect of antihistaminic agent meclastine on plasma ACTH. Acta Endocrinologica (Copenhagen) 94, 143-144.
4. Amsterdam JD, Maislin G, Skolnick B, Berwish N, Winokur A (1989). Multiple hormone responses to clonidine administration in depressed patients and healthy volunteers. Biological Psychiatry 26, 265-278.
5. Anderson IM, Cowen PJ (1986). Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Psychopharmacology 89, 131-133.
6. Aron DC, Findling JW, Tyrrell JB (2001). Glucocorticoids and adrenal androgens. In: Greenspan FS, Gardner DG (Eds.), Basic and Clinical Endocrinology (pp. 334-376). New York: McGraw-Hill.
7. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia : a comparison with haloperidol and placebo. Biological Psychiatry 42, 233-246.
8. Asnis GM, Sanderson WC, van Praag HM (1992). Cortisol response to intramuscular desipramine in patients with major depression and normal control subjects: a replication study. Psychiatry Research 44, 237-250.
9. 2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behavioural Brain Research 73, 277-280.
10. 2 dopamine receptors stimulate hvpothalamo-pitiutary-adrenal activity in rats. Neuropharmacology 31, 671-678.
11. Caccia S (2000). Biotransformation of post-clozapine antipsychotics. Clinical Pharmacokinetics 38, 393-414.
12. Calogero AE, Bagdy G, Moncada ML, D'agata R (1993). Effect of selective agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells. Journal of Endocrinology 136, 381-387.
13. De Visser SJ, van der Post J, Pieters SM, Cohen AF, van Gerven JMA (2001). Biomarkers for the effects of antipsychotic drugs in healthy volunteers. British Journal of Clinical Pharmacology 51, 119-132.
14. Eaton MJ, Lookingland KJ, Moore KE (1996). The σ receptor ligand rimcazole alters secretion of prolactin and α-melanocyte stimulating hormone by dopaminergic and non-dopaminergic mechanisms. European Journal of Pharmacology 299, 171-177.
15. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L (1972). Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. Journal of Clinical Endocrinology and Metabolism 35, 665-670.
16. First MB, Gibbon MSW, Spitzer RL, Williams JBW (1996). User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders - Research Version (SCID-I, version 2.0). New York: Biometrics Research.
17. 2 receptors. European Journal of Pharmacology 179, 103-109.
18. Garver DL (2000). Review of quetiapine side effects. Journal of Clinical Psychiatry 61 (Suppl. 8), 31-33.
19. 2-Adrenergic receptor-mediated regulation of growth hormone secretion in meal-fed Holstein steers (43669). Proceedings of the Society for Experimental Biology and Medicine 204, 318-322.
20. Gordin A, Mustajoki P, Pelkonen R (1985). Ketanserin without effects on basal anterior pituitary hormone secretion in healthy subjects. Journal of Endocrinological Investigation 8, 73-75.
21. Green B (1999). Focus on quetiapine. Current Medical Research and Opinion 15, 145-151.
22. Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY (1987). Journal of Neural Transmission 68, 227-240.
23. Gudelsky GA, Nash JF (1992). Neuroendocrinological and neurochemical effects of sigma ligands. Neuropharmacology 31, 157-162.
24. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003). Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28, 53-67.
25. Iyengar S, Mick S, Dilworth VM, Michel J, Rao TS, Farah JM, Wood PL (1990). Sigma receptors modulate the hypothalamic-pituitary-adrenal (HPA) axis centrally: evidence for a functional interaction with NMDA receptors, in vivo. Neuropharmacology 29, 299-303.
26. Iyengar S, Wood PL, Mick SJ, Dilworth VM, Gray NM, Farah JM, Rao TS, Contreras PC (1991). (+)3-[3-hydroxyphenyl-N-(1-propyl) piperidine] selectively differentiates effects of sigma ligands on neurochemical pathways modulated by sigma receptors: evidence for subtypes, in vivo. Neuropharmacology 30, 915-922.
27. Jørgensen H, Knigge U, Kjær A, Warberg J (1996). Interactions of histaminergic and serotonergic neurons in the hypothalamic regulation of prolactin and ACTH secretion. Neuroendocrinology 64, 329-336.
28. Jørgensen H, Knigge U, Warberg J (1993). Effect of selective serotonin receptor agonists on prolactin secretion in male rats. Neuroendocrinology 57, 401-407.
29. Kapur S, Remington G (2001). Atypical antipsychotics: new directions and challenges in the treatment of schizophrenia. Annual Review of Medicine 52, 503-517.
30. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 158, 360-369.
31. 2 receptor occupancy. Archives of General Psychiatry 57, 553-559.
32. Karbon EW, Abreu ME, Erickson RH, Kaiser C, Natalie Jr. KJ, Clissold DB, Borosky S, Bailey M, Martin LA, Pontecorvo MJ (1993). NPC 16377, a potent and selective σ-ligand. I. receptor binding, neurochemical and neuroendocrine profile. Journal of Pharmacology and Experimental Therapeutics 265, 866-874.
33. Kiem DT, Barna I, Koenig JI, Makara GB (1995). Adrenocorticotropin, prolactin and beta-endorphin stimulatory actions of alpha-2-adrenoceptor antagonists. Neuroendocrinology 61, 152-158.
34. King DJ, Link CGG, Kowalcyk B (1998). A comparison of bid and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berlin) 137, 139-146.
35. 2 receptors. European Journal of Endocrinology 139, 238-243.
36. Knigge U, Matzen S, Bach FW, Bang P, Warberg J (1989). Involvement of histaminergic neurons in the stress-induced release of pro-opiomelanocortin- derived peptides in rats. Acta Endocrinologica (Copenhagen) 120, 533-539.
37. 2-receptors: dependence on routes of administration. Neuroendocrinology 44, 41-48.
38. Knigge U, Thuesen B, Christiansen PM (1986a). Histaminergic regulation of prolactin secretion: dose response relationship and possible involvement of the dopaminergic system. Journal of Clinical Endocrinology and Metabolism 62, 491-496.
39. 2 adrenergic receptor antagonist idazoxan: comparison with yohimbine. Life Sciences 44, 809-818.
40. Laakmann G, Schüle C, Baghai T, Waldvogel E (1999). Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male volunteers. Psychoneuroendocrinology 24, 769-784.
41. Labrie F, Giguere V, Proulx L, Lefevre G (1984). Interactions between CRF, epinephrine, vasopressin and glucocorticoids in the control of ACTH secretion. Journal of Steroid Biochemistry 20, 153-160.
42. Levy AD, Van der Kar LD (1992). Endocrine and receptor pharmacology of serotonergic anxyolitics, antipsychotics and antidepressants. Life Sciences 51, 83-94.
43. Lima L, Arce V, Tresguerres JAF, Devesa J (1993). Clonidine potentiates the growth hormone (GH) response to GH-releasing hormone in norepinephrine synthesis-inhibited rats: evidence for an alpha-2-adrenergic control of hypothalamic release of somatostatin. Neuroendocrinology 57, 1155-1160.
44. Lingjaerde O, Ahlfors UG, Bech P, Denker SJ, Elgen K (1987). The UKU side effect rating scale. Acta Psychiatrica Scandinavica 76 (Suppl. 334), 81-94.
45. Lowy MT, Meltzer HY (1988). Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biological Psychiatry 23, 818-828.
46. Markowitz JS, Brown CS, Moore TR (1999). Atypical antipsychotics part I: Pharmacology, pharmacokinetics, and efficacy. Annals of Pharmacotherapy 33, 73-85.
47. McMahon CD, Chapin LT, Radcliff RP, Lookingland KJ, Tucker HA (2001). Somatostatin inhibits alpha-2-adrenergic-induced secretion of growth hormone-releasing hormone. Neuroendocrinology 73, 417-425.
48. Meltzer HY, Deutch AY (1999). Neurochemistry of schizophrenia. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (Eds.), Basic Neurochemistry: Molecular, Cellular and Medical Aspects (pp. 1053-1072). Philadelphia: Lippincott-Raven.
49. Monteleone P (1991). Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology 5, 61-64.
50. Netti C, Guidobono F, Olgiati VR, Sibilia V, Pagani F, Pecile A (1982). Influence of brain histaminergic system on episodic growth hormone secretion in the rat. Neuroendocrinology 35, 43-47.
51. Netti C, Sibilia V, Guidobono F, Pecile A (1993). Influence of brain histamine on growth hormone secretion induced by alpha-2-receptor activation. Neuroendocrinology 57, 1066-1070.
52. 2 agonist, (±)-1-(2,5-dimethoxy-4- bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration. Journal of Pharmacology and Experimental Therapeutics 256, 795-800.
53. Pechnick RN, Poland EP (1994). Neuroendocrine responses produced by enantiomeric pairs of drugs that interact with phencyclidine and σ receptors. European Journal of Pharmacology 263, 115-120.
54. 2 receptors on prolactin and luteinizing hormone release in humans: sex differences and the role of stress. Journal of Clinical Endocrinology and Metabolism 52, 924-928.
55. Roberts F, Calcutt CR (1983). Histamine and the hypothalamus. Neuroscience 9, 721-739.
56. 2 receptors. Psychopharmacology (Berlin) 140, 120-122.
57. Schilling JC, Adamus WS, Palluk R (1992). Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clinical Pharmacology and Therapeutics 51, 541-548.
58. Schüle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G (2002). The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology 163, 95-101.
59. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG (1997). Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Archives of General Psychiatry 54, 549-557.
60. Tuomisto J, Mannisto P (1985). Neurotransmitter regulation of anterior pituitary hormones. Pharmacological Reviews 37, 249-332.
61. Tsujimoto S, Okumura Y, Kamei C, Tasaka K (1993). Effects of intracerebroventricular injection of histamine and related compounds on corticosterone release in rats. British Journal of Pharmacology 109, 807-813.
62. Turrone P, Kapur S, Seeman MV, Flint AJ (2002). Elevation of prolactin levels by atypical antipsychotics. American Journal of Psychiatry 159, 133-135.
63. Van Praag HM, Lemus C, Kahn R (1986). The pitfalls of serotonin precursors as challengers in hormonal probes of central serotonin activity. Psychopharmacology Bulletin 22, 565-570.
64. Wetzel H, Szegedi A, Hain Ch, Wiesner J, Schlegel S, Benkert O (1995). Seroquel (ICI 204 636), a putative 'atypical' antipsychotic, in schizophrenia with positive simptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology (Berlin) 119, 231-238.